Fundz

RedHill acquires Ferring's Rebyota and Clenpiq rights

Asset purchase. This is a purchase of assets, contracts or a business line, not of a whole company.

PUBLIC · RDHLSep 01, 2026

Buyer

RedHill Biopharma Ltd

RaleighManufacturingBiotechnologyHealthcareSoftwareHealth CareScience And Engineering

Description

RedHill Biopharma announced the acquisition of exclusive global and U.S. commercialization rights to Ferring's Rebyota and Clenpiq. The deal, valued at $12 million upfront plus potential royalties, is part of RedHill's strategic repositioning in the gastrointestinal market. The drugs generated approximately $37.5 million in 2025 net sales, enhancing RedHill's commercial prospects and liquidity.

Other recent acquisitions in Healthcare and Science And Engineering

Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.

Who to call at RedHill Biopharma Ltd, and when

When RedHill Biopharma Ltd changes hands, the new owners review vendors, systems and leadership. That is when the door opens.

  • An alert the day RedHill Biopharma Ltd raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at RedHill Biopharma Ltd, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at RedHill Biopharma Ltd. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

RedHill Biopharma Ltd

Location

Raleigh, North Carolina, United States

About

RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company focused on developing and commercializing therapies for gastrointestinal, infectious, and oncological diseases in the U.S. The company markets Talicia®, an FDA-approved treatment for H. pylori infection, and is advancing late-stage programs including opaganib, a first-in-class SPHK2 inhibitor; RHB-204 for Crohn’s disease and nontuberculous mycobacteria (NTM) infections; RHB-107 (upamostat) for COVID-19 and inflammatory diseases; and RHB-102 for nausea, vomiting, and IBS-D.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment RedHill Biopharma Ltd makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Gilead
Likely contact at this company
••••••••@••••••••

See Gilead's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for RedHill Biopharma Ltd's next move

Learn about Strategic plan

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.